We believe in promoting cellular wellness through cellular restoration.
RJX is a fixed combination intravenous (IV) drug therapy technology platform designed to contribute multiple modes of action having the capacity to address a variety of unmet medical needs.
Current commercially available drugs commonly target a single mode of action, often with the goal of delaying progression of symptoms but with minimum action against the disease itself. As a result, many of these medical approaches lack the tools to address the roots of disease progression.
RJX was formulated to promote cell health at its foundation and Reven believes it holds great promise, not just to promote recovery but also to re-define wellness as determined by quality of life. Because RJX is believed to act on multiple common points of cellular failure, Reven considers RJX to be a platform formulation. As such, it is believed to have the capacity to address a variety of unmet medical needs.
Reven views RJX as a tool to serve distinct families of potential modalities, with each focusing on different diseases across therapeutic areas. The goal then is to develop our RJX technology platform to revolutionize medicine as applied towards many diseases. The RJX platform supports design of medicines for a diverse array of applications by scientifically grouping shared product features and recognizing areas where customization may further improve outcomes. Reven believes the design of the RJX platform technology will enable us to develop diverse therapies for an array of medical indications
In 2008, Reven initiated compassionate care use with RJX technology in South Africa for patients with limited to no therapeutic options. This opportunity to aid patients also greatly improved Reven’s understanding of the product, enhancing knowledge in areas of dosing, product stabilization, patient healing trajectories, and outcome analysis.
Reven’s recent drug provision through the Australian Government’s Therapeutic Goods Administration Special Access Scheme and pilot research completed in companion animals has fueled Reven’s knowledge base in support of further investigations into RJXs capacity for multiple treatment modalities.
10+ years of research now including data generated from Reven’s Phase 1 Food and Drug Administration (FDA) approved clinical safety study (ClinicalTrials.gov; ID NCT03680105), continues to provide insight into the capabilities of the RJX technology to promote wellness. Reven intends to further assess these insights in upcoming Phase 2 clinical trials.
Reven continues to prioritize the research and development of multi-modal medicines intended to positively impact patients throughout global communities.
Reven is dedicated to investigating neglected diseases with unmet therapeutic needs and areas of medicine where current standard of care is often not successful. Our goal is to deliver innovative medicines based on the RJX technology to patients in need.
Our mission is dedicated to the service of patients and the families who cherish them. Collaboration with academia, clinical researchers, providers and patients to address unmet medical needs continues to educate and humble us.
Reven’s overall goal is to advance patient survivability and improve patient quality of life demonstrated by reduced pain, removal of disease, enhanced mobility, increased vitality, improved quality of rest, and restoration of body balance so that patients can re-engage with their lives.
Advancing RJX Medicine